Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major
about
Recent developments and future prospects in the treatment of visceral leishmaniasisKinetoplastid Membrane Protein-11 as a Vaccine Candidate and a Virulence Factor in LeishmaniaStrategies to overcome antileishmanial drugs unresponsivenessSingle dose novel Salmonella vaccine enhances resistance against visceralizing L. major and L. donovani infection in susceptible BALB/c miceB7-H1 blockade increases survival of dysfunctional CD8(+) T cells and confers protection against Leishmania donovani infectionsCytotoxic T cells mediate pathology and metastasis in cutaneous leishmaniasisProphylactic DNA vaccine for hepatitis C virus (HCV) infection: HCV-specific cytotoxic T lymphocyte induction and protection from HCV-recombinant vaccinia infection in an HLA-A2.1 transgenic mouse model.Differences in immune responses against Leishmania induced by infection and by immunization with killed parasite antigen: implications for vaccine discoveryCytokine responses to novel antigens in an Indian population living in an area endemic for visceral leishmaniasisDNA-protein immunization using Leishmania peroxidoxin-1 induces a strong CD4+ T cell response and partially protects mice from cutaneous leishmaniasis: role of fusion murine granulocyte-macrophage colony-stimulating factor DNA adjuvantProtection against intestinal amebiasis by a recombinant vaccine is transferable by T cells and mediated by gamma interferon.Testing of four Leishmania vaccine candidates in a mouse model of infection with Leishmania (Viannia) braziliensis, the main causative agent of cutaneous leishmaniasis in the New World.Molecular cloning, cell localization and binding affinity to DNA replication proteins of the p36/LACK protective antigen from Leishmania infantum.From genomes to vaccines: Leishmania as a model.A novel Leishmania infantum recombinant antigen which elicits interleukin 10 production by peripheral blood mononuclear cells of patients with visceral leishmaniasis.Evaluation of Leishmania donovani protein disulfide isomerase as a potential immunogenic protein/vaccine candidate against visceral LeishmaniasisLeishmania chagasi T-cell antigens identified through a double library screenMapping the antigenicity of the parasites in Leishmania donovani infection by proteome serologyAscorbate peroxidase from Leishmania major controls the virulence of infective stage of promastigotes by regulating oxidative stress.Main features of DNA-based immunization vectors.Vaccination with trypomastigote surface antigen 1-encoding plasmid DNA confers protection against lethal Trypanosoma cruzi infection.Acquired resistance but not innate resistance to Mycobacterium bovis bacillus Calmette-Guérin is compromised by interleukin-12 ablationCross-protective efficacy of a prophylactic Leishmania donovani DNA vaccine against visceral and cutaneous murine leishmaniasisPotency, efficacy and durability of DNA/DNA, DNA/protein and protein/protein based vaccination using gp63 against Leishmania donovani in BALB/c mice.Interleukin-12 is capable of generating an antigen-specific Th1-type response in the presence of an ongoing infection-driven Th2-type response.TLR1/2 activation during heterologous prime-boost vaccination (DNA-MVA) enhances CD8+ T Cell responses providing protection against Leishmania (Viannia)Leishmaniasis: current status of vaccine developmentT-cell-mediated immune responses in patients with cutaneous or mucosal leishmaniasis: long-term evaluation after therapy.Conditions influencing the efficacy of vaccination with live organisms against Leishmania major infectionThe magnitude of CD4(+) T-cell activation rather than TCR diversity determines the outcome of Leishmania infection in mice.Memory CD8+ T cells protect dendritic cells from CTL killing.Immunostimulatory DNA as an adjuvant in vaccination against Leishmania major.Predominance of CD4 Th1 and CD8 Tc1 cells revealed by characterization of the cellular immune response generated by immunization with a DNA vaccine containing a Trypanosoma cruzi gene.Complete protection against lethal Toxoplasma gondii infection in mice immunized with a plasmid encoding the SAG1 gene.Subunit vaccination of mice against new world cutaneous leishmaniasis: comparison of three proteins expressed in amastigotes and six adjuvants.Listeria monocytogenes as a short-lived delivery system for the induction of type 1 cell-mediated immunity against the p36/LACK antigen of Leishmania major.Activation of skin dendritic cells by immunostimulatory DNA.Vervet monkeys vaccinated with killed Leishmania major parasites and interleukin-12 develop a type 1 immune response but are not protected against challenge infectionLeishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasisDifferences in gamma interferon production in vitro predict the pace of the in vivo response to Leishmania amazonensis in healthy volunteers.
P2860
Q26740563-8738AC7A-397A-41F7-B44F-239BA9183EF4Q26777203-4D6C0079-5C50-49DE-AE49-D387A7D313D0Q26849297-6F38D26B-9C0B-4D98-8B72-BB387A215072Q27305906-8D0A270D-6EEC-41B1-A237-08B5017B5F42Q27317015-3B6299C4-1BB7-4B72-8BFD-217D1EB15F1CQ27334358-778857CA-3381-40C9-B01F-EDB9741483A3Q27488288-A151B8B0-139D-4203-97F9-AED88187A666Q28077110-9505583B-533F-4CDD-8BDB-90F94FBAB9D0Q28485121-77BD8A15-7966-45D8-BAC9-C4041C51727FQ28542668-57EA2AB6-5796-4259-8556-77FCCE9A92D0Q30436915-9CF2EE34-5784-4747-814F-49CCE4058C21Q30444062-E7E79280-E68C-4F4D-A90F-BECC74665725Q30657332-90D0E757-4E0C-4213-BD63-F806D1ADDF5CQ30811325-31DF8751-0772-4F83-86CC-A687C440B6E2Q30833358-37232412-873E-4A28-8EA2-A6465688B4DBQ31060208-F412C80E-F003-40C2-8939-68D30B60D281Q33258365-EBC1AD53-4B59-4550-A4BB-3CF1815C7B76Q33267301-73B0EC89-08F9-4079-A911-EBC72A30D6BAQ33619356-A939F08D-2CA7-4B74-AD4E-FAE3D80DE90EQ33646629-DFA8378C-825F-4A26-84E3-CB9F1E6DEE21Q33767207-4F09AFD9-8930-4C4C-BDB8-79E2767D286FQ33767573-FB77A886-2101-4500-A7AD-8FE2DC7C7E07Q33796005-575041D0-BB53-4A49-8800-9740AD79C3BDQ33818084-C19EE508-9096-447C-A3E1-FC57224303A4Q33866879-5F79490A-23BF-470C-BCED-1CA9F49C2E5FQ33939303-91ED0A8C-698A-408E-9E7A-8DBE8500777FQ33941719-5C5F0923-889B-4ED7-9953-8FFD530471FAQ33942376-3A734E3D-B94E-401D-AB97-8335C8E0A36BQ33946585-51ACB3F9-FE5D-4C07-84CC-3E6160467DC8Q33988743-EBB41D84-A434-444F-83D1-4176A458E5CBQ34000039-2756557D-8675-4208-B90B-86876BFBFC46Q34001298-9505B1A2-6243-4337-BE00-4E724A0C9E69Q34001352-1BF97FDB-7002-44B3-A06F-DB6B5527DF49Q34002711-B0397438-9ED2-4485-B8DF-5EF133AC243DQ34003547-BFED2545-B7BA-41E3-9A2E-9EFEDA86E231Q34003632-D313F3F1-F16A-4ECF-997D-0CF16232AA1AQ34005392-5055E256-C84E-4495-8D6D-38324AA3F2F7Q34005577-A7D60393-55E5-459B-8620-A7D46A6E4E1EQ34008441-B87E980F-746F-4032-9252-4A7C4D42D011Q34009680-3288EE51-578F-406F-A0C6-B69801A14D88
P2860
Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年学术文章
@wuu
1997年学术文章
@zh-cn
1997年学术文章
@zh-hans
1997年学术文章
@zh-my
1997年学术文章
@zh-sg
1997年學術文章
@yue
1997年學術文章
@zh
1997年學術文章
@zh-hant
name
Vaccination with DNA encoding ...... infected with Leishmania major
@ast
Vaccination with DNA encoding ...... infected with Leishmania major
@en
type
label
Vaccination with DNA encoding ...... infected with Leishmania major
@ast
Vaccination with DNA encoding ...... infected with Leishmania major
@en
prefLabel
Vaccination with DNA encoding ...... infected with Leishmania major
@ast
Vaccination with DNA encoding ...... infected with Leishmania major
@en
P2093
P2860
P356
P1476
Vaccination with DNA encoding ...... infected with Leishmania major
@en
P2093
N Glaichenhaus
S Gurunathan
S L Reiner
P2860
P304
P356
10.1084/JEM.186.7.1137
P407
P577
1997-10-01T00:00:00Z